NCT06525220招募中3 期
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Merus B.V.
- 入组人数
- 700
- 试验地点
- 372
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
详细描述
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ HNSCC. HNSCC patients should not have had previous systemic therapy administered in the incurable recurrent or metastatic setting, although previous systemic therapy as part of multimodal treatment for locally advanced disease is allowed if PD was ≥6 months after the last platinum-containing therapy dose. Previous treatments with anti PD-(L)1 or anti-EGFR therapies are not allowed. In the case of cetuximab, patients who have received cetuximab with radiotherapy as a local treatment and PD was >1 year after the last dose of cetuximab are eligible.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed ICF before initiation of any study procedures
- •Age ≥ 18 years at signing of ICF
- •Histologically confirmed HNSCC with evidence of metastatic or locally recurrent disease not amenable to local therapy with curative intent.
- •The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
- •HNSCC patients eligible to receive pembrolizumab as 1L monotherapy with tumors expressing PD-L1, CPS ≥
- •HNSCC patients should not have had previous systemic therapy administered in the incurable recurrent or metastatic setting
- •A new tumor biopsy, unless the patient has an available archival tumor sample with sufficient material
- •Measurable disease per Investigator assessment as defined by RECIST v1.1 by radiologic methods
- •ECOG Performance Status (PS) of 0-1
- •Life expectancy ≥ 12 weeks, as per investigator assessment.
- •Left ventricular ejection fraction (LVEF) ≥50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
- •Adequate organ function as defined per protocol.
- •HIV-positive patients are eligible only if the cluster of differentiation 4 (CD4+) count is ≥ 300/µl, viral load is undetectable, and the patient is currently receiving highly active antiretroviral therapy
排除标准
- •Central nervous system metastases that are untreated or already treated but symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 21 days prior to randomization
- •Known leptomeningeal involvement
- •Any systemic anticancer therapy or investigational drug within 4 weeks or 5 half-lives, whichever is shorter, before randomization
- •Requirement for immunosuppressive medication
- •Major surgery or radiotherapy within 3 weeks of randomization
- •Clinically significant toxicities related to prior anticancer therapies that have not returned to ≤ Grade 1 or baseline except for Grade ≤2- myalgia, neuropathy, alopecia, and any prior therapy related endocrinopathies
- •History of hypersensitivity reaction to any of the excipients of petosemtamab or pembrolizumab.
- •Unstable angina; history of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment; or history of myocardial infarction within 6 months prior to randomization
- •History of prior malignancies within the last 5 years, with the exception of excised local cancer
- •Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy
- •Current serious illness or medical conditions including, but not limited to, uncontrolled active infection, clinically significant pulmonary, metabolic or psychiatric disorders
- •Patients with known infectious diseases as per protocol.
- •Pregnant or breastfeeding patients.
- •The patient has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy of prednisone >10 mg/day or equivalent, or any other form of immunosuppressive therapy
- •The patient has an active autoimmune disease that has required systemic immune suppressive treatment in the past 2 years; replacement therapy is not considered immune suppressive treatment
- •The patient has had an allogeneic tissue/solid organ transplant.
- •Patient has a primary tumor site of nasopharynx, or sinonasal carcinoma (any histology)
- •Other protocol defined inclusion/exclusion criteria may apply.
研究组 & 干预措施
Petosemtamab + Pembrolizumab
Experimental
Combination Therapy
干预措施: Petosemtamab (Drug)
Petosemtamab + Pembrolizumab
Experimental
Combination Therapy
干预措施: Pembrolizumab (Drug)
Pembrolizumab
Active Comparator
Monotherapy
干预措施: Pembrolizumab (Drug)
结局指标
主要结局
Overall Survival (OS)
时间窗: Up to approximately 3 years
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR)
时间窗: Up to approximately 2 years
次要结局
- Time to response (TTR) per RECIST v1.1 as assessed by BICR(Time Frame: Up to approximately 2 years)
- Time to response (TTR) per RECIST v1.1 as assessed by Investigator(Time Frame: Up to approximately 2 years)
- Progression Free Survival (PFS) per RECIST v1.1 as assessed by BICR(Up to approximately 2 years)
- Duration of Response (DOR) per RECIST v1.1 as assessed by BICR(Up to approximately 2 years)
- Objective response rate per RECIST v1.1 as assessed by investigator review(Up to approximately 2 years)
- Progression-free survival per RECIST v1.1 as assessed by investigator review(Up to approximately 2 years)
- Duration of response per RECIST v1.1 as assessed by investigator review(Up to approximately 2 years)
- Clinical benefit rate per RECIST v1.1 as assessed by BICR(Up to approximately 2 years)
- Clinical benefit rate per RECIST v1.1 as assessed by investigator review(Up to approximately 2 years)
- Number of participants who experienced at least one treatment emergent adverse event (TEAE)(Up to 30 days post last dose)
- Number of participants who experienced at least one serious TEAE(Up to 30 days post last dose)
- Number of participants who discontinued study treatment due to TEAEs(Up to 30 days post last dose)
- Number of participants who had dose modification due to TEAEs(Up to 30 days post last dose)
- To evaluate patient reported outcomes for health-related quality of life(Up to approximately 2 years)
- Pharmacokinetic parameters(Up to first 6 cycles)
- Incidence of anti-drug antibodies (ADAs)(Up to 30 days post last dose)
研究者
研究点 (372)
Loading locations...
相似试验
进行中（未招募）
3 期
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)Head and Neck Squamous Cell CarcinomaNCT06496178Merus B.V.621
终止
3 期
Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised LipodystrophyGeneralized LipodystrophyNCT06502990Amryt Pharma1
招募中
3 期
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerOvarian CancerNCT06394492Suzhou Suncadia Biopharmaceuticals Co., Ltd.440
已完成
3 期
Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)Acute Ischaemic StrokeNCT03541668Tasly Biopharmaceuticals Co., Ltd.674
进行中（未招募）
3 期
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaUntreated Chronic Lymphocytic LeukemiaNCT04075292AstraZeneca155